Nevro Corp. (NYSE:NVRO) has received a consensus recommendation of “Buy” from the thirteen analysts that are presently covering the firm. Two equities research analysts have rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $70.67.

A number of brokerages have commented on NVRO. B. Riley reissued a “buy” rating on shares of Nevro Corp. in a research report on Friday, September 16th. Wells Fargo & Co. began coverage on shares of Nevro Corp. in a research report on Tuesday, July 12th. They issued an “outperform” rating on the stock. Piper Jaffray Cos. began coverage on shares of Nevro Corp. in a research report on Friday, July 22nd. They issued an “overweight” rating on the stock. William Blair reissued an “outperform” rating on shares of Nevro Corp. in a research report on Monday, July 18th. Finally, Bank of America Corp. assumed coverage on shares of Nevro Corp. in a research report on Monday, August 8th. They issued a “buy” rating on the stock.

Shares of Nevro Corp. (NYSE:NVRO) traded down 2.430% on Friday, hitting $93.745. 342,650 shares of the company traded hands. Nevro Corp. has a 12 month low of $36.51 and a 12 month high of $106.93. The stock’s 50-day moving average price is $97.76 and its 200-day moving average price is $78.28. The company’s market capitalization is $2.67 billion.

A number of hedge funds have recently modified their holdings of NVRO. Royal Bank of Canada boosted its stake in shares of Nevro Corp. by 1,246,130.0% in the first quarter. Royal Bank of Canada now owns 249,246 shares of the company’s stock worth $14,022,000 after buying an additional 249,226 shares in the last quarter. Seven Eight Capital LLC acquired a new stake in shares of Nevro Corp. during the first quarter worth $214,000. Cormorant Asset Management LLC boosted its stake in shares of Nevro Corp. by 82.9% in the first quarter. Cormorant Asset Management LLC now owns 485,386 shares of the company’s stock worth $27,308,000 after buying an additional 220,000 shares in the last quarter. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Nevro Corp. during the first quarter worth $380,000. Finally, Bellevue Group AG acquired a new stake in shares of Nevro Corp. during the first quarter worth $422,000.

Nevro Corp. Company Profile

Nevro Corp. is a medical device company. The Company has developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company’s Senza system is a spinal cord stimulation (SCS) system that delivers its HF10 therapy. HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain.

5 Day Chart for NYSE:NVRO

Receive News & Stock Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related stocks with our FREE daily email newsletter.